Pandemic preparedness: Toward a universal influenza vaccine

Drug News and Perspectives

Volumn 22, Issue 2, 2009, Pages 80-92

  Roose, Kenny ^a   Fiers, Walter ^a   Saelens, Xavier ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE BASED VACCINE; DNA DIRECTED RNA POLYMERASE; DNA VACCINE; EPITOPE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MATRIX PROTEIN; NONSTRUCTURAL PROTEIN 1; NUCLEOPROTEIN; NUCLEOPROTEIN 2 ECTODOMAIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

AMINO ACID SEQUENCE; AVIAN INFLUENZA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC; REVIEW; VACCINE PRODUCTION; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

AMINO ACID SEQUENCE; ANIMALS; CIVIL DEFENSE; CLINICAL TRIALS AS TOPIC; DISEASE OUTBREAKS; EPITOPES; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

EID: 65649134734     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2009.22.2.1334451     Document Type: Review

References (160)

1. Hobson, D., Curry, R.L., Beare, A.S. et al. The role of serum hoemogglutinotion-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972, 70: 767-77.
2. Ghedin, E., Sengamallay, N.A., Shumway, M. et al. Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 2005, 437(7062): 1162-6.
3. Lindstrom, S.E., Hiromoto, Y., Nishimura, H. et al. Comparative analysis of evolutionary mechanisms of the hemagglutinin and three internal protein genes of influenza B virus: multiple cocirculating lineages and frequent reassortment of the NP, M, and NS genes. J Virol 1999, 73(5): 4413-26.
4. McCullers, J.A., Wang, G.C., He, S. et al. Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature. J Virol 1999, 73(9): 7343-8.
5. Nelson, M.I., Edelman, L., Spiro, D.J. et al. Molecular epidemiology of A/H3N2 and A/H1N1 influenza virus during a single epidemic season in the United States. PLoS Pathog 2008, 4: e1000133.
6. Fouchier, R.A., Munster, V., Wallensten, A. et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 2005, 79(5): 2814-22.
7. Wong, S.S. and Yuen, K.Y. Avian influenza virus infections in humans. Chest 2006, 129(1): 156-68.
8. Chen, L.M., Davis, C.T., Zhou, H. et al. Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. PLoS Pathog 2008, 4(5): e1000072.
9. Gabriel, G., Dauber, B., Wolff, T et al. The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host. Proc Natl Acad Sci U S A 2005, 102(51): 18590-5.
10. Fang, R., Min Jou, W., Huylebroeck, D. et al. Complete structure of A/ duck/Ukraine/63 influenza hemagglutinin gene: animal virus as progenitor of human H3 Hong Kong 1968 influenza hemagglutinin. Cell 1981, 25(2): 315-23.
11. Gething, M.J., Bye, J., Skehel, J. et al. Cloning and DNA sequence of double-stranded copies of haemagglutinin genes from H2 and H3 strains elucidates antigenic shift and drift in human influenza virus. Nature 1980, 287(5780): 301-6.
12. Scholtissek, C., Rohde, W., Von Hoyningen, V. and Rott, R. On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology 1978, 87(1): 13-20.
13. Russell, C.J. and Webster, R.G. The genesis of a pandemic influenza virus. Cell 2005, 123(3): 368-71.
14. Stevens, J., Blixt, O., Chen, L.M. et al. Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J Mol Biol 2008, 381(5): 1382-94.
15. Taubenberger, J.K., Reid, A.H., Lourens, R.M. et al. Characterization of the 1918 influenza virus polymerase genes. Nature 2005, 437(7060): 889-93.
16. de Jong, J.C., Beyer, W.E., Palache, A.M. et al. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000, 61(1): 94-9.
17. Kilbourne, E.D., Smith, C., Brett, I. et al. The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic. Proc Natl Acad Sci U S A 2002, 99(16): 10748-52.
18. Skowronski, D.M., Masaro, C., Kwindt, T.L. et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007, 25(15): 2842-51.
19. Teare, E.L., Rawes, J.C., Chakraverty, P. et al. Failure of influenza vaccine to prevent two successive outbreaks of influenza A H1N1 in a school community. Br J Gen Pract 1990, 40(330): 10-2.
20. Hehme, N., Engelmann, H., Kunzel, W. et al. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol. 2002, 191(3-4): 203-8.
21. El Sahly, H.M. and Ketel, W.A. Pandemic H5N1 influenza vaccine development: on update. Expert Rev Vaccines 2008, 7(2): 241-7.
22. Keitel, W.A. and Atmar, R.L. Preparing for a possible pandemic: influenza A/H5N1 vaccine development. Curr Opin Pharmacol 2007, 7(5): 484-90.
23. Leroux-Roes, I., Borkowski, A., Vanwolleghem, T. et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370(9587): 580-9.
24. de Wit, E., Munster, V.J., Spronken, M.I. et al. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. J Virol 2005, 79(19): 12401-7.
25. Joseph, T, McAuliffe, J., Lu, B. et al. A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology 2008, 378(1): 123-32.
26. Pappas, C., Matsuoka, Y, Swayne, D.E. and Donis, R.O. Development and evaluation of an influenza virus subtype H7N2 vaccine candidate for pandemic preparedness. Clin Vaccine Immunol 2007, 14(11): 1425-32.
27. Chen, H., Subbarao, K., Swayne, D. et al. Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. Vaccine 2003, 21(17-18): 1974-9.
28. Du, N., Li, W., Li, Y. et al. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses. Vaccine 2008, 26(23): 2912-8.
29. Johnson, N.P. and Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 2002, 76(1): 105-15.
30. Epstein, S.L. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 2006, 193(1): 49-53.
31. Viboud, C., Grais, R.F., Lafont, B.A. et al. Multinational impact of the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic. J Infect Dis 2005, 192(2): 233-48.
32. Monto, A.S. and Kendal, A.P. Effect of neurominidase antibody on Hong Kong influenza. Lancet 1973, 1(7804): 623-5.
33. Kilbourne, E.D., Johansson, B.E. and Grajower, B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neurominidase glycoproteins. Proc Natl Acad Sci U S A 1990, 87(2): 786-90.
34. Bui, H.H., Peters, B., Assarsson, E., Mbawuike, I. and Sette, A. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci U S A 2007, 104(1): 246-51.
35. Schulman, J.L. and Kilbourne, E.D. Induction of partial specific heterotypic immunity in mice by a single infection with influenza a virus. J Bacteriol 1965, 89: 170-4.
36. Braciale, T.J. Immunologic recognition of influenza virus-infected cells. I. Generation of a virus-strain specific and a cross-reactive subpopulation of cytotoxic T cells in the response to type A influenza viruses of different subtypes. Cell Immunol 1977, 33(2): 423-36.
37. Doherty, P.C., Effros, R.B. and Bennink, J. Heterogeneity of the cytotoxic response of thymus-derived lymphocytes after immunization with influenza viruses. Proc Natl Acad Sci U S A 1977, 74(3): 1209-13.
38. Effros R.B., Doherty, P.C., Gerhard, W. and Bennink, J. Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. J Exp Med 1977, 145(3): 557-68.
39. Zweerink, H.J., Courtneidge, S.A., Skehel, J.J. et al. Cytotoxic T cells kill influenza virus infected cells but do not distinguish between serologically distinct type A viruses. Nature 1977, 267(5609): 354-6.
40. Yap, K.L. and Ada, G.L. The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen. Scand J Immunol 1978, 8(5): 413-20.
41. Yap, K.L., Ada, G.L. and McKenzie, I.F. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 1978, 273(5659): 238-9.
42. Bennink, J., Effros, R.B. and Doherty, P.C. Influenzal pneumonia: early appearance of cross-reactive T cells in lungs of mice primed with heterologous type A viruses. Immunology 1978, 35(3): 503-9.
43. Ennis, F.A., Wells, M.A., Butchko, GM. and Albrecht, P. Evidence that cytotoxic T cells are part of the host's response to influenza pneumania. J Exp Med 1978, 148(5): 1241-50.
44. Portela, A. and Digard, P. The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J Gen Virol 2002, 83(Pt. 4): 723-34.
45. Townsend, A.R. and Skehel, J.J. The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J Exp Med 1984, 160(2): 552-63.
46. Taylor, P.M. and Askonas, B.A. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 1986, 58(3): 417-20.
47. Wraith, D.C., Vessey, A.E. and Askonas, B.A. Purified influenza virus nucleoprotein protects mice from lethal infection. J Gen Virol 1987, 68 (Pt 2): 433-40.
48. Carragher, D.M., Kaminski, D.A., Moquin, A. et al. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 2008, 181(6): 4168-76.
49. Belz, G.T., Stevenson, P.G. and Doherty, P.C. Contemporary analysis of MHC-related immunodominance hierarchies in the CD8+ T cell response to influenza A viruses. J Immunol 2000, 165(5): 2404-9.
50. Yewdell, J.W. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. Immunity 2006, 25(4): 533-43.
51. Zhong, W., Reche, P.A., Lai, C.C. et al. Genome-wide characterization of a viral cytotoxic T lymphocyte epitope repertoire. J Biol Chem 2003, 278(46): 45135-44.
52. Crowe, S.R., Turner, S.J., Miller, S.C. et al. Differential antigen presentation regulates the changing patterns of CD8+ T cell immunodominance in primary and secondary influenza virus infections. J Exp Med 2003, 198(3): 399-410.
53. Boon, A.C., de Mutsert, G., Graus, Y.M. et al. The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype. J Virol 2002, 76(2): 582-90.
54. Wang, M., Lamberth, K., Harndahi, M. et al. CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. Vaccine 2007, 25(15): 2823-31.
55. Krejjtz, J.H., de Mutsert, G., van Baalen, C.A. et al. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 2008, 82(12): 5161-6.
56. Rimmelzwaan, G.F., Boon, A.C., Voeten, J.T. et al. Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. Virus Res 2004, 103(1-2): 97-100.
57. Maassab, H.F. Adaptation and growth characteristics of influenza virus at 25 degrees c. Nature 1967, 213(5076): 612-4.
58. Jin, H., Zhou, H., Lu, B. and Kemble, G. Importing temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from cold-adapted A/Ann Arbor/6/60. J Virol 2004, 78(2): 995-8.
59. Tsfasman, T.M., Markushin, S.C., Akopova, I.I. et al. Molecular mechanisms of reversion to the ts+ (non-temperature-sensitive) phenotype of influenza A cold-adapted (ca) virus strains. J Gen Virol 2007, 88(Pt. 10): 2724-9.
60. Gabriel, G., Garn, H., Wegmann, M. et al. The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine. Vaccine 2008, 26(7): 956-65.
61. Horimoto, T, Takada, A., Iwatsuki-Horimoto, K. et al. A protective immune response in mice to viral components other than hemogglutinin in a live influenza A virus vaccine model. Vaccine 2004, 22(17-18): 2244-7.
62. Vincent, A.L., Ma, W., Lager, K.M. et al. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine 2007, 25(47): 7999-8009.
63. Powell, T.J., Strutt, T., Reome, J. et al. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against suprolethal challenge with heterosubtypic virus. J Immunol 2007, 178(2): 1030-8.
64. Gorse, G.J., O'Connor, T.Z., Newman, F.K. et al. Immunity to influenza in older adults with chronic obstructive pulmonary disease. J Infect Dis 2004, 190(1): 11-9.
65. Mendelman, P.M., Rappaport, R., Cho, I. et al. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr Infect Dis J 2004, 23(11): 1053-5.
66. Halloran, M.E., Piedra, P.A., Longini, I.M. Jr. et al. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine 2007, 25(20): 4038-45.
67. Burlington, D.B., Wright, P.F., van Wyke, K.L. et al. Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children. J Clin Microbiol 1985, 21(5): 847-9.
68. Steinhoff, M.C., Fries, L.F., Karron, R.A. et al. Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children. J Clin Microbiol 1993, 31(4): 836-8.
69. He, X.S., Holmes, T.H., Zhang, C. et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 2006, 80(23):11756-66.
70. Gao, W., Soloff, A.C., Lu, X. et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006, 80(4):1959-64.
71. Hoelscher, M.A., Garg, S., Bangari, D.S. et al. Development of adenovirol-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006, 367(9509): 475-81.
72. Veits, J., Romer-Oberdorfer, A., Helferich, D. et al. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 2008, 26(13): 1688-96.
73. Ulmer, J.B., Donnelly, J.J., Parker, S.E. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259(5102): 1745-9.
74. Lalor, P.A., Webby, R.J., Morrow, J. et al. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/ Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 2008, 197(12): 1643-52.
75. Lu, S., Wang, S. and Grimes-Serrano, J.M. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008, 7(2): 175-91.
76. Morein, B., Sundquist, B., Hoglund, S. et al. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984, 308(5958): 457-60.
77. Voeten, J.T., Rimmelzwaan, G.F., Nieuwkoop, N.J. et al. Introduction of the haemagglutinin transmembrane region in the influenza virus matrix protein facilitates its incorporation into ISCOM and activation of specific CD8(+) cytotoxic T lymphocytes. Vaccine 2000, 19(4-5): 514-22.
78. Paillot, R., Grimmett, H., Elton, D. and Daly, J.M. Protection, systemic IFNgamma, and antibody responses induced by on ISCOM-based vaccine against a recent equine influenza virus in its natural host. Vet Res 2008, 39(3): 21.
79. Rimmelzwaan, G.F., Baars, M., van Beek, R. et al. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol 1997, 78(Pt 4): 757-65.
80. Rimmelzwaan, G.F., Claas, E.C., van Amerongen, G. et al. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 1999, 17(11-12): 1355-8.
81. Sambhara, S., Kurichh, A., Miranda, R. et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 2001, 211(2): 143-53.
82. Sambhara, S., Woods, S., Arpino, R. et al. Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes. J Infect Dis 1998, 177(5): 1266-74.
83. Takada, A., Matsushita, S., Ninomiya, A. et al. Intranosal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 2003, 21(23): 3212-8.
84. Raviv, Y., Bercovid, T., Gitler, C. and Salomon, Y. Selective photoinduced uncoupling of the response of adenylate cyclose to gonadotropins by 5-iodonaphthyl 1-azide. Biochemistry 1984, 23(3): 503-8.
85. Raviv, Y., Blumenthal, R., Tompkins, S.M. et al. Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. J Virol 2008, 82(9): 4612-9.
86. Tumpey, T.M., Renshaw, M., Clements, J.D. and Katz, J.M. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001, 75(11): 5141-50.
87. Agren, L.C., Ekman, L., Lowenadler, B. and Lycke, N.Y. Genetically engineered nontoxic vaccine adjuvant that combines 8 cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 1997, 158(8): 3936-46.
88. De Filette, M., Ramne, A., Birkett, A. et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 2006, 24(5): 544-51.
89. Eliasson, D.G., El Bakkouri, K., Schon, K. et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008, 26(9): 1243-52.
90. Ichinohe, T., Tamura, S., Kawaguchi, A. et al. Cross-protection against HSN1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 2007, 196(9): 1313-20.
91. Lidbury, B.A., Grissell, T.V., Sizer, P.J. et al. Studies on the IgA-independent immunological responses in mice to influenza virus challenge after oral vaccination with irradiated whole virus and an erythrocyte complex. Immunol Cell Biol 2000, 78(2): 149-55.
92. Song, J.H., Nguyen, H.H., Cuburu, N. et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A 2008, 105(5): 1644-9.
93. Johansson, B.E., Bucher, D.J. and Kilbourne, E.D. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 1989, 63(3): 1239-46.
94. Matrosovich, M.N., Matrosovich, T.Y., Gray, T. et al. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 2004, 78(22): 12665-7.
95. Johansson, B.E., Moran, T.M., Bona, C.A. et al. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J Immunol 1987, 139(6): 2010-4.
96. Sandbulte, M.R., Jimenez, G.S., Boon, A.C. et al. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007, 4(2): e59.
97. Brett, I.C. and Johansson, B.E. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neurominidase vaccines in a murine model system. Virology 2005, 339(2): 273-80.
98. Deroo, T., Jou, W.M. and Fiers, W. Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 1996, 14(6): 561-9.
99. Johansson, B.E. and Kilbourne, E.D. Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition. Proc Natl Acad Sci U S A 1994, 91(6): 2358-61.
100. Johansson, B.E., Pokorny, B.A. and Tiso, V.A. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine 2002, 20(11-12): 1670-4.
101. Holsinger, L.J. and Lamb, R.A. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 1991, 183(1): 32-43.
102. Sugrue, R.J. and Hay, A.J. Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 1991, 180(2): 617-24.
103. Lamb, R.A., Zebedee, S.L. and Richardson, C.D. Influenza virus M2 protein is on integral membrane protein expressed on the infected-cell surface. Cell 1985, 40(3): 627-33.
104. Zebedee, S.L. and Lamb, R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988, 62(8): 2762-72.
105. Hu, J., Fu, R., Nishimura, K. et al. Histidines, heart of the hydrogen ion channel from influenza A virus: toward an understanding of conductance and proton selectivity. Proc Natl Acad Sci U S A 2006, 103(18): 6865-70.
106. Venkataraman, P., Lamb, R.A. and Pinto, L.H. Chemical rescue of histidine selectivity filter mutants of the M2 ion channel of influenza A virus. J Biol Chem 2005, 280(22): 21463-72.
107. Wang, C., Lamb, R.A. and Pinto, L.H. Activation of the M2 ion channel of influenza virus: a role for the transmembrane domain histidine residue. Biophys J 1995, 69(4): 1363-71.
108. Zhirnov, O.P. Isolation of matrix protein M1 from influenza viruses by acid-dependent extraction with nonionic detergent. Virology 1992, 186(1): 324-30.
109. Sugrue, R.J., Bahadur, G., Zambon, M.C. et al. Specific structural alteration of the influenza haemagglutinin by amantadine. EMBO J 1990, 9(11): 3469-76.
110. Roberts, P.C. and Compans, R.W. Host cell dependence of viral morphology. Proc Natl Acad Sci U S A 1998, 95(10): 5746-51.
111. Roberts, P.C., Lamb, R.A. and Compans, R.W. The M1 and M2 proteins of influenza A virus ore important determinants in filamentous particle formation. Virology 1998, 240(1): 127-37.
112. McCown, M.F. and Pekosz A. The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. J Virol 2005, 79(6): 3595-605.
113. McCown, M.F. and Pekosz, A. Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J Virol 2006, 80(16): 8178-89.
114. Lamb, R.A. and Lai, C.J. Conservation of the influenza virus membrane protein (M1) amino acid sequence and an open reading frame of RNA segment 7 encoding a second protein (M2) in H1N1 and H3N2 strains. Virology 1981, 112(2): 746-51.
115. Black, R.A., Rota, P.A., Gorodkova, N. et al. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J Gen Virol 1993, 74(Pt 1): 143-6.
116. Feng, J., Zhang, M., Mozdzanowska, K. et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 2006, 3: 102.
117. Liu, W., Li, H. and Chen, Y.H. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol 2003, 35(2):141-6.
118. Leser, G.P. and Lamb, R.A. Influenza virus assembly and budding in roft-derived microdomains: a quontitative analysis of the surface distribution of HA, NA and M2 proteins. Virology 2005, 342(2): 215-27.
119. Schroeder, C., Heider, H., Moncke-Buchner, E. and Lin, T.I. The influenza virus ion channel and maturation cofactor M2 is a cholesterol-binding protein. Eur Biophys J 2005, 34(1): 52-66.
120. Park, E.K., Castrucci, M.R., Portner, A. et al. The M2 ectodomain is important for its incorporation into influenza A virions. J Virol 1998, 72:2449-55.
121. Treanor, J.J., Tierney, E.L., Zebedee, S.L. et al. Passively transferred monoclonal anti-body to the M2 protein inhibits influenza A virus replication in mice. J Virol 1990, 64(3): 1375-7.
122. Neirynck, S., Deroo, T, Saelens, X. et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5(10):1157-63.
123. Frace, A.M., Klimov, A.I., Rowe, T. et al. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 1999,17(18): 2237-44.
124. Slepushkin, V.A., Katz, J.M., Black, R.A. et al. Protection of mice against influenza A virus challenge by vaccination with boculovirus-expressed M2 protein. Vaccine 1995, 13(15): 1399-402.
125. Tompkins, S.M., Zhao, Z.S., Lo, C.Y. et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007,13(3): 426-35.
126. Jegerlehner, A., Schmitz, N., Storni, T. and Bachmann, M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004,172(9): 5598-605.
127. Wang, R., Song, A., Levin, J. et al. Therapeutic potential of a fully human monoclonal anti-body against influenza A virus M2 protein. Antiviral Res 2008, 80(2):168-77.
128. Zebedee, S.L. and Lamb, R.A. Growth restriction of influenza A virus by M2 protein anti-body is genetically linked to the M1 protein. Proc Natt Acad Sci U S A 1989, 86(3):1061-5.
129. Zharikova, D., Mozdzanowska, K., Feng, J. et al. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 2005, 79(11): 6644-54.
130. Skehel, J.J. and Wiley, D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000, 69: 531-69.
131. Kido, H., Murakami, M., Oba, K. et al. Cellular proteinases trigger the infectivity of the influenza A and Sendai viruses. Mol Cells 1999, 9(3): 235-44.
132. Bianchi, E., Liang, X., Ingallinella, P. et al. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J Virol 2005, 79(12): 7380-8.
133. Horvath, A., Toth, G.K., Gogolak, P. et al. A hemagglutinin-based multipeptide construct elicits enhanced protective immune response in mice against influenza A virus infection. Immunol Lett 1998, 60(2-3): 127-36.
134. Steinhauer, D.A., Wharton, S.A., Skehel, J.J. and Wiley, D.C. Studies of the membrane fusion activities of fusion peptide mutants of influenza virus hemagglutinin. J Virol 1995, 69(11): 6643-51.
135. DiBrino, M., Tsuchida, T., Turner, R.V. et al. HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs. J Immunol 1993, 151(11): 5930-5.
136. Berkhoff, E.G., de Wit, E., Geelhoed-Mieras, M.M. et al. Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes. J Virol 2005, 79(17): 11239-46.
137. Gotch, F., Rothbard, J., Howland, K. et al. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 1987, 326(6116): 881-2.
138. Jameson, J., Cruz, J. and Ennis, F.A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol 1998, 72(11): 8682-9.
139. Jameson, J., Cruz, J., Terajima, M. and Ennis, F.A. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 1999,162(12):7578-83.
140. McMichael, A.J., Gotch, F.M. and Rothbard, J. HLA B37 determines on influenza A virus nucleoprotein epitope recognized by cytotoxic T lymphocytes. J Exp Med 1986,164(5): 1397-406.
141. Tussey, L.G., Rowland-Jones, S., Zheng, T.S. et al. Different MHC class I alleles compete for presentation of overlapping viral epitopes. Immunity 1995, 3(1): 65-77.
142. Belshe, R.B. Current status of live attenuated influenza virus vaccine in the US. Virus Res 2004, 103(1-2): 177-85.
143. Belshe, R.B., Edwards, K.M., Vesikari, T. et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007,356(7): 685-96.
144. Suguitan, A.L. Jr., McAuliffe, J., Mills, K.L. et al. Live, attenuated influenza A H5N7 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006, 3(9): e360.
145. Desheva, J.A., Lu, X.H., Rekstin, A.R. et al. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pondemic potential. Vaccine 2006, 24(47-48): 6859-66.
146. Ehrlich, H.J., Muller, M., Oh, H.M. et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008, 358(24): 2573-84.
147. Lin, J., Zhang, J., Dong, X. et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006, 368(9540): 991-7.
148. Bresson, J.L., Perronne, C., Launay, O. et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/ 2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367(9523): 1657-64.
149. Treanor, J.J., Campbell, J.D., Zangwill, K.M. et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354(13):1343-51.
150. Nicholson, K.G., Colegate, A.E., Podda, A. et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/ Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357(9272):1937-43.
151. Stephenson, I., Zambon, M.C., Rudin, A. et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006, 80(10): 4962-70.
152. Stephenson, I., Nicholson, K.G., Gluck, R. et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003, 362(9400): 1959-66.
153. Atmar, R.L., Keitel, W.A., Patel, S.M. et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006, 43(9):1135-42.
154. Treanor, J.J., Wilkinson, B.E., Masseoud, F. et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001,19(13-14): 1732-7.
155. Song, L., Nakaar, V., Kavita, U. et al. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE 2008, 3(5): e2257.
156. Bright, R.A., Carter, D.M., Crevar, C.J. et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 2008, 3(1): e1501.
157. De Filette, M., Min Jou, W., Birkett, A. et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005, 337(1): 149-61.
158. Bessa, J., Schmitz, N., Hinton, H.J. et al. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 2008, 38(1): 114-26.
159. Huleatt, J.W., Nakaar, V., Desai, P. et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flogellin. Vaccine 2008, 26(2): 201-14.
160. Fan, J., Liang, X., Horton, M.S. et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22(23-24): 2993-3003.